15-min delayed · Jul 28, 3:45 PM ET · Get real-time quotes →
The Quantellect read.Of the 2 firms covering Nuvectis Pharma Inc, 2 rate it Buy or better, 0 sit at Hold, and 0 rate it Sell or worse, a strong buy consensus. Targets are tightly clustered, $33.00 to $39.00, so the covering firms are broadly aligned. The average target of $36.00 sits 82% above the current $19.78. The rating mix has stayed broadly stable, with Buy-side ratings edging up from 1 to 2 over recent months. On the fundamentals, the Street sees consensus EPS building from about $-0.26 next quarter toward $-1.05 the year after.Descriptive synthesis of third-party analyst data, not a Quantellect rating or recommendation.
ANALYST CONSENSUS2 ratings
Strong Buy
Strong Buy00%
Buy2100%
Hold00%
Sell00%
Strong Sell00%
Based on 2 analysts giving stock ratings to Nuvectis Pharma Inc.
As of Jul, 2 of 2 firms rate NVCT a Buy (0 Hold, 0 Sell), the standing distribution of every covering firm's most recent active call.
NVCT EPS & revenue forecast
EPS · NEXT QUARTER
$-0.26
Range $-0.31 – $-0.20 · 5 analysts · -42% YoY
Next period, 5 analysts expect Nuvectis Pharma Inc to earn $-0.26 a share (range $-0.31 – $-0.20), versus $-0.44 a year earlier. Full-year consensus is $-1.02, growing to $-1.05 the year after.
REVENUE · NEXT QUARTER
$0
Range $0 – $0 · 5 analysts
Revenue is expected to reach $0 (range $0 – $0). Full-year consensus is $0, rising to $0 next year.
Top analysts covering Nuvectis Pharma Inc
Ranked by each analyst's overall Quantellect track record across all the stocks they cover, shown with their current call on NVCT.
#1
Joseph Pantginis
HC Wainwright & Co. · Rank #266
Buy
$39.00+97.2% to target
Overall win rate
32%
+ Follow
#2
Jonathan Aschoff
Roth MKM · Rank #383
Buy
$33.00+66.8% to target
Overall win rate
28%
+ Follow
#3
NR
Naz Rahman
Maxim Group
Buy
$17.00-14.1% to target
Coverage
—
+ Follow
#4
YJ
Yale Jen
Laidlaw & Co.
Buy
$19.00-3.9% to target
Coverage
—
+ Follow
NVCT stock forecast FAQ
What is NVCT's average 12-month price target?+
The 2 analysts with a live target average $36.00 for Nuvectis Pharma Inc over the next 12 months, ranging from a $39.00 high to a $33.00 low.
Is NVCT stock a Buy, Sell or Hold right now?+
The current consensus is Strong Buy. Of the 2 analyst ratings, 2 are Buy or Strong Buy, 0 are Hold, and 0 are Sell or Strong Sell.
What are the highest and lowest price targets for NVCT?+
The Street-high target is $39.00 (HC Wainwright & Co.), and the Street-low is $33.00 (Roth Capital). The average of all 2 active targets is $36.00.
How many Wall Street analysts cover NVCT?+
2 analysts have an active rating on Nuvectis Pharma Inc, and 2 firms carry a live 12-month price target.
Who is the most accurate analyst covering NVCT?+
Among analysts who currently cover NVCT, Joseph Pantginis of HC Wainwright & Co. has the strongest overall Quantellect track record (Rank #266). Their current call is Buy with a $39.00 target.
What is Nuvectis Pharma Inc's projected EPS for next quarter?+
The consensus estimate is $-0.26 per share (range $-0.31 – $-0.20) across 5 analysts. Full-year EPS is projected at $-1.02, rising to $-1.05 the following year.
How much revenue is Nuvectis Pharma Inc expected to report next quarter?+
Consensus revenue is $0 (range $0 – $0). Full-year revenue is projected at $0, growing to $0 next year.
Have analysts been upgrading or downgrading NVCT lately?+
As of Jul, 2 of 2 firms rate NVCT a Buy (0 Hold, 0 Sell), the standing distribution of every covering firm's most recent active call.
How are the analysts on this page ranked?+
By each analyst's overall Quantellect track record — a sample-adjusted measure of how accurate their calls have been across every stock they cover. We do not rank on their NVCT calls alone, since a single stock is too small a sample to be reliable.
Which data on this page is live, and how often does it update?+
Price and daily change are 15-minute delayed market data. Analyst ratings, targets, consensus and earnings estimates are aggregated from multiple data providers and refresh daily.
Disclaimer: Ratings, price targets, consensus and earnings estimates on this page describe third-party analyst research aggregated from multiple data providers and refreshed daily; price and daily change are 15-minute delayed. These are historical opinions, not recommendations, and nothing on this page, including The Quantellect read, is a rating, a price target, or investment advice from Quantellect. Always do your own research and consult a licensed financial advisor before making investment decisions.
